Trial Profile
Pilot Study of Tissue and Hematopoietic/Mesenchymal Stem Cell Collection for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- 12 Jun 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 12 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Jun 2022 Planned number of patients changed from 20 to 40.